Company intelligence / Profile preview
PLL Therapeutics
Francepll-therapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
PLL Therapeutics is a clinical-stage biopharmaceutical company developing a polypeptide-based therapeutic and companion diagnostics targeting the root causes of neurodegenerative and autoimmune disorders. Its lead candidate, PLL001, is in Phase I/II trials for ALS. The company combines early diagnostics with multi-target therapies to address multifactorial CNS and GI diseases. No published efficacy results yet.
- Therapeutic areas
- ImmunologyNeurology
- Modalities
- Chemical drugsPolypeptide delivery platformMulti-target therapeutics
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
CRO partner – ALITHIA Life SciencesCDMO partner – CURAPATH
Beyond the preview
Go deeper on PLL Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLL Therapeutics.